Skip to content

Study · Randomized controlled trial · n = 521 · 2014

12 results

Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage.

Seo YS, Park SY, Kim MY, Kim JH, Park JY, Yim HJ, Jang BK, Kim HS, Hahn T, Kim BI, Heo J, An H and 7 more

Show all authors

Tak WY, Baik SK, Han KH, Hwang JS, Park SH, Cho M, Um SH

Hepatology (Baltimore, Md.)25 Jul 2014Cited by 141 (Europe PMC)

PMID24415445 (opens in a new tab)DOI10.1002/hep.27006 (opens in a new tab)PepBankPUB-24415445
Source linkPubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In variceal bleeding, treatment success by day 5 was 83.8% with octreotide versus 86.2% with terlipressin.

    In plain wordsIn variceal bleeding, treatment success was numerically lower with octreotide than terlipressin.

    Peptide
    Octreotide
    Outcome
    DecreaseTreatment success by day 5
    Study

    n = 521

    Comparator
    Terlipressin
    Analysis
    Primary
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Treatment success rate
    83.8%
    octreotide
    Treatment success rate
    86.2%
    terlipressin
    P value
    0.636
    three-group comparison (terlipressin, somatostatin, octreotide)

    Source sentences

    Summary
    and treatment success was achieved by day 5 in 86.2%, 83.4%, and 83.8% (P=0.636),
    3 context sentences
    Summary · context
    Patients with liver cirrhosis and significant upper gastrointestinal bleeding were randomly assigned to receive early administration of terlipressin, somatostatin, or octreotide, followed by endoscopic treatment.
    Summary · context
    In total, 780 patients with variceal bleeding were enrolled: 261 in the terlipressin group; 259 in the somatostatin group; and 260 in the octreotide group.
    Summary · context
    The primary endpoint was 5-day treatment success, defined as control of bleeding without rescue treatment, rebleeding, or mortality, with a noninferiority margin of 0.1.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In variceal bleeding, treatment success by day 5 was 83.8% with octreotide versus 83.4% with somatostatin.

    In plain wordsIn variceal bleeding, treatment success was numerically higher with octreotide than somatostatin.

    Peptide
    Octreotide
    Outcome
    IncreaseTreatment success by day 5
    Study

    n = 519

    Comparator
    Somatostatin
    Analysis
    Primary
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Treatment success rate
    83.8%
    octreotide
    Treatment success rate
    83.4%
    somatostatin
    P value
    0.636
    three-group comparison (terlipressin, somatostatin, octreotide)

    Source sentences

    Summary
    and treatment success was achieved by day 5 in 86.2%, 83.4%, and 83.8% (P=0.636),
    3 context sentences
    Summary · context
    Patients with liver cirrhosis and significant upper gastrointestinal bleeding were randomly assigned to receive early administration of terlipressin, somatostatin, or octreotide, followed by endoscopic treatment.
    Summary · context
    In total, 780 patients with variceal bleeding were enrolled: 261 in the terlipressin group; 259 in the somatostatin group; and 260 in the octreotide group.
    Summary · context
    The primary endpoint was 5-day treatment success, defined as control of bleeding without rescue treatment, rebleeding, or mortality, with a noninferiority margin of 0.1.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In variceal bleeding, active bleeding at initial endoscopy occurred in 43.5% with octreotide versus 43.7% with terlipressin.

    In plain wordsIn variceal bleeding, active bleeding at initial endoscopy was similar with octreotide and terlipressin.

    Peptide
    Octreotide
    Outcome
    DecreaseActive bleeding at initial endoscopy
    Study

    n = 521

    Comparator
    Terlipressin
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Active bleeding rate
    43.5%
    octreotide
    Active bleeding rate
    43.7%
    terlipressin
    P value
    0.748
    three-group comparison (terlipressin, somatostatin, octreotide)

    Source sentences

    Summary
    At the time of initial endoscopy, active bleeding was noted in 43.7%, 44.4%, and 43.5% of these patients, respectively (P=0.748),
    2 context sentences
    Summary · context
    Patients with liver cirrhosis and significant upper gastrointestinal bleeding were randomly assigned to receive early administration of terlipressin, somatostatin, or octreotide, followed by endoscopic treatment.
    Summary · context
    In total, 780 patients with variceal bleeding were enrolled: 261 in the terlipressin group; 259 in the somatostatin group; and 260 in the octreotide group.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In variceal bleeding, control without rescue occurred in 88.1% with octreotide versus 89.7% with terlipressin.

    In plain wordsIn variceal bleeding, control without rescue was numerically lower with octreotide than terlipressin.

    Peptide
    Octreotide
    Outcome
    DecreaseBleeding control without rescue
    Study

    n = 521

    Comparator
    Terlipressin
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Control without rescue rate
    88.1%
    octreotide
    Control without rescue rate
    89.7%
    terlipressin
    P value
    0.752
    three-group comparison (terlipressin, somatostatin, octreotide)

    Source sentences

    Summary
    with similar rates of control of bleeding without rescue treatment (89.7%, 87.6%, and 88.1%; P=0.752),
    2 context sentences
    Summary · context
    Patients with liver cirrhosis and significant upper gastrointestinal bleeding were randomly assigned to receive early administration of terlipressin, somatostatin, or octreotide, followed by endoscopic treatment.
    Summary · context
    In total, 780 patients with variceal bleeding were enrolled: 261 in the terlipressin group; 259 in the somatostatin group; and 260 in the octreotide group.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In variceal bleeding, rebleeding occurred in 4.4% with octreotide versus 3.4% with terlipressin.

    In plain wordsIn variceal bleeding, rebleeding was numerically higher with octreotide than terlipressin.

    Peptide
    Octreotide
    Outcome
    IncreaseRebleeding
    Study

    n = 521

    Comparator
    Terlipressin
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Rebleeding rate
    4.4%
    octreotide
    Rebleeding rate
    3.4%
    terlipressin
    P value
    0.739
    three-group comparison (terlipressin, somatostatin, octreotide)

    Source sentences

    Summary
    rebleeding (3.4%, 4.8%, and 4.4%; P=0.739),
    2 context sentences
    Summary · context
    Patients with liver cirrhosis and significant upper gastrointestinal bleeding were randomly assigned to receive early administration of terlipressin, somatostatin, or octreotide, followed by endoscopic treatment.
    Summary · context
    In total, 780 patients with variceal bleeding were enrolled: 261 in the terlipressin group; 259 in the somatostatin group; and 260 in the octreotide group.
  6. 06HumanRandomized controlled trialSafety outcome

    In variceal bleeding, mortality was 8.8% with octreotide versus 8.0% with terlipressin.

    In plain wordsIn variceal bleeding, mortality was numerically higher with octreotide than terlipressin.

    Peptide
    Octreotide
    Outcome
    IncreaseMortality
    Study

    n = 521

    Comparator
    Terlipressin
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Measurements

    Mortality rate
    8.8%
    octreotide
    Mortality rate
    8%
    terlipressin
    P value
    0.929
    three-group comparison (terlipressin, somatostatin, octreotide)

    Source sentences

    Summary
    or mortality (8.0%, 8.9%, and 8.8%; P=0.929).
    2 context sentences
    Summary · context
    Patients with liver cirrhosis and significant upper gastrointestinal bleeding were randomly assigned to receive early administration of terlipressin, somatostatin, or octreotide, followed by endoscopic treatment.
    Summary · context
    In total, 780 patients with variceal bleeding were enrolled: 261 in the terlipressin group; 259 in the somatostatin group; and 260 in the octreotide group.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In variceal bleeding, the absolute lower confidence bound for terlipressin versus octreotide was 0.090, with a noninferiority margin of 0.1.

    In plain wordsIn variceal bleeding, the absolute lower confidence bound for terlipressin versus octreotide was 0.090, with a noninferiority margin of 0.1.

    Peptide
    Octreotide
    Outcome
    Not applicableTreatment-success confidence bound
    Study

    n = 521

    Comparator
    Terlipressin
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Absolute lower bound of confidence interval
    0.09
    terlipressin versus octreotide

    Source sentences

    Summary
    The absolute values of the lower bound of confidence intervals for terlipressin versus somatostatin, terlilpressin versus octreotide, and octreotide versus somatostatin were 0.095, 0.090, and 0.065, respectively.
    3 context sentences
    Summary · context
    Patients with liver cirrhosis and significant upper gastrointestinal bleeding were randomly assigned to receive early administration of terlipressin, somatostatin, or octreotide, followed by endoscopic treatment.
    Summary · context
    In total, 780 patients with variceal bleeding were enrolled: 261 in the terlipressin group; 259 in the somatostatin group; and 260 in the octreotide group.
    Summary · context
    The primary endpoint was 5-day treatment success, defined as control of bleeding without rescue treatment, rebleeding, or mortality, with a noninferiority margin of 0.1.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In variceal bleeding, active bleeding at initial endoscopy occurred in 43.5% with octreotide versus 44.4% with somatostatin.

    In plain wordsIn variceal bleeding, active bleeding at initial endoscopy was similar with octreotide and somatostatin.

    Peptide
    Octreotide
    Outcome
    DecreaseActive bleeding at initial endoscopy
    Study

    n = 519

    Comparator
    Somatostatin
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Active bleeding rate
    43.5%
    octreotide
    Active bleeding rate
    44.4%
    somatostatin
    P value
    0.748
    three-group comparison (terlipressin, somatostatin, octreotide)

    Source sentences

    Summary
    At the time of initial endoscopy, active bleeding was noted in 43.7%, 44.4%, and 43.5% of these patients, respectively (P=0.748),
    2 context sentences
    Summary · context
    Patients with liver cirrhosis and significant upper gastrointestinal bleeding were randomly assigned to receive early administration of terlipressin, somatostatin, or octreotide, followed by endoscopic treatment.
    Summary · context
    In total, 780 patients with variceal bleeding were enrolled: 261 in the terlipressin group; 259 in the somatostatin group; and 260 in the octreotide group.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In variceal bleeding, control without rescue occurred in 88.1% with octreotide versus 87.6% with somatostatin.

    In plain wordsIn variceal bleeding, control without rescue was numerically higher with octreotide than somatostatin.

    Peptide
    Octreotide
    Outcome
    IncreaseBleeding control without rescue
    Study

    n = 519

    Comparator
    Somatostatin
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Control without rescue rate
    88.1%
    octreotide
    Control without rescue rate
    87.6%
    somatostatin
    P value
    0.752
    three-group comparison (terlipressin, somatostatin, octreotide)

    Source sentences

    Summary
    with similar rates of control of bleeding without rescue treatment (89.7%, 87.6%, and 88.1%; P=0.752),
    2 context sentences
    Summary · context
    Patients with liver cirrhosis and significant upper gastrointestinal bleeding were randomly assigned to receive early administration of terlipressin, somatostatin, or octreotide, followed by endoscopic treatment.
    Summary · context
    In total, 780 patients with variceal bleeding were enrolled: 261 in the terlipressin group; 259 in the somatostatin group; and 260 in the octreotide group.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In variceal bleeding, rebleeding occurred in 4.4% with octreotide versus 4.8% with somatostatin.

    In plain wordsIn variceal bleeding, rebleeding was numerically lower with octreotide than somatostatin.

    Peptide
    Octreotide
    Outcome
    DecreaseRebleeding
    Study

    n = 519

    Comparator
    Somatostatin
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Rebleeding rate
    4.4%
    octreotide
    Rebleeding rate
    4.8%
    somatostatin
    P value
    0.739
    three-group comparison (terlipressin, somatostatin, octreotide)

    Source sentences

    Summary
    rebleeding (3.4%, 4.8%, and 4.4%; P=0.739),
    2 context sentences
    Summary · context
    Patients with liver cirrhosis and significant upper gastrointestinal bleeding were randomly assigned to receive early administration of terlipressin, somatostatin, or octreotide, followed by endoscopic treatment.
    Summary · context
    In total, 780 patients with variceal bleeding were enrolled: 261 in the terlipressin group; 259 in the somatostatin group; and 260 in the octreotide group.
  11. 11HumanRandomized controlled trialSafety outcome

    In variceal bleeding, mortality was 8.8% with octreotide versus 8.9% with somatostatin.

    In plain wordsIn variceal bleeding, mortality was numerically lower with octreotide than somatostatin.

    Peptide
    Octreotide
    Outcome
    DecreaseMortality
    Study

    n = 519

    Comparator
    Somatostatin
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Measurements

    Mortality rate
    8.8%
    octreotide
    Mortality rate
    8.9%
    somatostatin
    P value
    0.929
    three-group comparison (terlipressin, somatostatin, octreotide)

    Source sentences

    Summary
    or mortality (8.0%, 8.9%, and 8.8%; P=0.929).
    2 context sentences
    Summary · context
    Patients with liver cirrhosis and significant upper gastrointestinal bleeding were randomly assigned to receive early administration of terlipressin, somatostatin, or octreotide, followed by endoscopic treatment.
    Summary · context
    In total, 780 patients with variceal bleeding were enrolled: 261 in the terlipressin group; 259 in the somatostatin group; and 260 in the octreotide group.
  12. 12HumanRandomized controlled trialEfficacy outcome

    In variceal bleeding, the absolute lower confidence bound for octreotide versus somatostatin was 0.065, with a noninferiority margin of 0.1.

    In plain wordsIn variceal bleeding, the absolute lower confidence bound for octreotide versus somatostatin was 0.065, with a noninferiority margin of 0.1.

    Peptide
    Octreotide
    Outcome
    Not applicableTreatment-success confidence bound
    Study

    n = 519

    Comparator
    Somatostatin
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Absolute lower bound of confidence interval
    0.065
    octreotide versus somatostatin

    Source sentences

    Summary
    The absolute values of the lower bound of confidence intervals for terlipressin versus somatostatin, terlilpressin versus octreotide, and octreotide versus somatostatin were 0.095, 0.090, and 0.065, respectively.
    3 context sentences
    Summary · context
    Patients with liver cirrhosis and significant upper gastrointestinal bleeding were randomly assigned to receive early administration of terlipressin, somatostatin, or octreotide, followed by endoscopic treatment.
    Summary · context
    In total, 780 patients with variceal bleeding were enrolled: 261 in the terlipressin group; 259 in the somatostatin group; and 260 in the octreotide group.
    Summary · context
    The primary endpoint was 5-day treatment success, defined as control of bleeding without rescue treatment, rebleeding, or mortality, with a noninferiority margin of 0.1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT05199038

Comparison of 2 Days Versus 5 Days of Octreotide After Endoscopic Therapy in Preventing Early Esophageal Varices Rebleed : A Randomized Controlled Study

Tanta Universityn = 184est. Jun 2022 to est. Nov 2023

Esophageal Varices

Trial pageClinicalTrials.govUpdated 18 May 2022
Status unknownPhase 4NCT04028323

Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Variceal Bleeding (CHESS1903)

Nanfang Hospital, Southern Medical Universityn = 6016 Jul 2019 to est. 15 Oct 2022

Renal Function Disorder · Acute Variceal Bleeding

Trial pageClinicalTrials.govUpdated 17 Aug 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.